These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11441328)

  • 1. Allergen-induced inflammation and the role of immunoglobulin E (IgE).
    Fendrick AM; Baldwin JL
    Am J Ther; 2001; 8(4):291-7. PubMed ID: 11441328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with a combination of anti-IgE and specific immunotherapy for allergic rhinitis and asthma.
    Hamelmann E; Rolinck-Werninghaus C; Wahn U; Kopp MV
    Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():303-13; discussion 313-5. PubMed ID: 20799475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic interventions for allergic rhinitis.
    Passalacqua G; Ciprandi G
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1615-25. PubMed ID: 17107285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for anti-IgE in combination with specific allergen immunotherapy?
    Hamelmann E; Rolinck-Werninghaus C; Wahn U
    Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):501-10. PubMed ID: 14612676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of allergic diseases with monoclonal anti-IgE antibody].
    Morita Y
    Nihon Rinsho; 2001 Oct; 59(10):2019-22. PubMed ID: 11676148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-IGE therapy in asthma].
    Mehiri Ben Rhouma N; Béji M; Louzir B; Daghfous J
    Tunis Med; 2002 Oct; 80(10):575-80. PubMed ID: 12632749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
    Chang TW; Wu PC; Hsu CL; Hung AF
    Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
    Verbruggen K; Van Cauwenberge P; Bachert C
    Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
    Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
    J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IgE in the treatment of allergic disorders in pediatrics.
    Fried AJ; Oettgen HC
    Curr Opin Pediatr; 2010 Dec; 22(6):758-64. PubMed ID: 20966754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
    Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
    BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab and hypersensitivity reactions.
    Shankar T; Petrov AA
    Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating atopic asthma with the anti-IgE monoclonal antibody.
    D'Amato G
    Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
    Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
    J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dermatological implications of omalizumab, an anti-IgE antibody].
    Di Lucca-Chrisment J
    Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis.
    Jahnz-Rózyk K; Targowski T; Głodzinska-Wyszogrodzka E; Płusa T
    Allergy; 2003 Jul; 58(7):595-601. PubMed ID: 12823117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab: a future innovation for treatment of severe ocular allergy?
    Williams PB; Sheppard JD
    Expert Opin Biol Ther; 2005 Dec; 5(12):1603-9. PubMed ID: 16318424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IgE therapy.
    Brownell J; Casale TB
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):551-68, v. PubMed ID: 15474858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.